HBV Forum 8 – Hepatitis B
21 June, 2022
London, UK
ENYO Pharma was attending HBV Forum 8 in London. The HBV Forum aims to advance the regulatory science for novel HBV therapeutic interventions and its associated morbidities in real time by providing an independent and neutral environment for ongoing multi-stakeholder dialogue.
https://forumresearch.org/hbv-forum/hbv-foruman-overview/
Read next in 'Events'
- The 2024 international workshop on Alport syndrome
- ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
- 6th CKD Summit – Chronic Kidney Disease Drug Development
- ASN Kidney Week
- Alport Connect 2023, the annual Alport syndrome patient and family meeting in US